Carbohydrate-Based Vaccines

From Concept to Clinic

A. Krishna Prasad (Redaktør)

The past three decades have witnessed the development and regulatory approval of glycoconjugate vaccines against several medically important bacterial pathogens, including Haemophilus influenzae type b, Streptococcus pneumoniae, Neisseria meningitides, and Salmonella typhi. Les mer
Vår pris
1941,-

(Innbundet) Fri frakt!
Leveringstid: Sendes innen 21 dager

Innbundet
Legg i
Innbundet
Legg i
Vår pris: 1941,-

(Innbundet) Fri frakt!
Leveringstid: Sendes innen 21 dager

Om boka

The past three decades have witnessed the development and regulatory approval of glycoconjugate vaccines against several medically important bacterial pathogens, including Haemophilus influenzae type b, Streptococcus pneumoniae, Neisseria meningitides, and Salmonella typhi. Immunologic protection against these and many other bacterial diseases is mediated through opsonophagocytic antibodies directed against the surface
carbohydrates that define the bacterial serogroup or serotype and serve as virulence factors. These vaccines are composed of bacterial capsular polysaccharides chemically conjugated to immunogenic carrier proteins. Given that the diseases caused by these bacterial pathogens are most pronounced in infants and young children, the development of the
glycoconjugate vaccine technology has had a considerable impact on public health.
Many of the chapters in this volume were assembled as a follow-up from a symposium entitled "Carbohydrate-Based Vaccines and Adjuvants" which took place at the 254th American Chemical Society National Meeting held in Washington, DC (August 2017). The symposium was sponsored by Pfizer and the Carbohydrate (CARB) and Biotechnology (BIOT) divisions. This book, therefore, reflects the importance of this field toward design, development, manufacture and licensure of the complex carbohydrate-based
(glycoconjugate) vaccines.
The book has been organized into thirteen chapters, which cover a comprehensive landscape including the clinical history, design, development, chemistry, manufacturing and control (CMC) aspects, pre-clinical assays, adjuvants and the various approaches used to develop carbohydrate-based vaccines.

Fakta

Om forfatteren

Dr. Krishna Prasad functioned as the Director of Vaccine Research and Development, at Pfizer. Dr. Prasad is a recognized industry leader in Vaccine Development and founder of Citranvi, LLC a pre-clinical stage Vaccines R & D company. He joined Wyeth-Lederle Vaccines and Pediatrics in 1998, which later became Pfizer. He has been named as an inventor or co-inventor in more than 150 granted patents world-wide, which played a significant role towards
the development and protection of Pfizer's diverse conjugate vaccine intellectual property portfolio. During his 20 years tenure at Wyeth/Pfizer, he successfully led many innovative and complex multi-component vaccine candidates through all stages of pre-clinical and clinical development through commercial licensure,
notably Pneumococcal conjugate vaccine (Prevnar-13 (R)), meningococcal (Meningitec (R)); and many clinical candidates such as staphylococcal, Group B Streptococcus (GBS) Respiratory Syncytial Virus (RSV) and A-?-Peptide-CRM197 conjugate

immunotherapeutic against Alzheimer's Disease. Dr. Prasad is an expert in design, research, early and late phase clinical development, scale-up, technology transfer, clinical trial material manufacturing under cGMP, trouble-shooting and commercialization of vaccines. He obtained his Ph. D. in Medicinal Chemistry of Natural Products from Central Drug Research Institute, Lucknow, India. After postdoctoral stints at University of Rhode Island and Case Western Reserve University he served as Asst.
Research Officer at the National Research Council Canada.